At Agenus, we believe vertical integration is critically important. We have taken aggressive steps to accomplish this, facilitating rapid and efficient advancement of our antibody programs and minimizing reliance on external vendors. Through innovation and strategic acquisitions, Agenus scientists have access to an unparalleled capabilities tool kit.
Performing early discovery work on novel antibodies, including validating targets and identifying lead compounds, is highly enabled by our mammalian, phage and yeast display platform technologies. Lead optimization and candidate verification benefit from our integrated discovery platforms, including our mammalian Retrocyte DisplayTM and HT-CHO technologies. These integrated platforms, along with our structural and computational biology capabilities, positions us to precisely control and design the properties of our antibodies so that we can generate products with the desired properties to enhance their efficacy.
We have also built our in-house cell line development and manufacturing capabilities, which we regard as an important advantage in an environment of increasingly tighter third party manufacturing capacities.
This integration of our discovery, development and manufacturing capabilities provides Agenus with unique advantages in an era when quality, efficiencies and speed of development and commercialization are paramount to successfully developing a new generation of I-O biopharmaceutical therapeutics.